Posted by Michael Wonder on 16 Sep 2017
Proposal to fund dexamethasone ocular implants for DMO
15 September 2017 - PHARMAC is seeking feedback on a proposal to list dexamethasone 700 mcg ocular implants (Ozurdex) through a provisional agreement with Allergan,
PHARMAC is proposing to list dexamethasone 700 mcg ocular implants in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 November 2017, subject to restrictions, for the treatment of diabetic macular oedema.
